Swiss’s Idorsia applies for the reimb of its first product
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.12.27 06:24:17
가나다라
0
Applies for reimb of its cerebral vasospasm prevention drug Pivlaz Inj, which is being sold by Handok
Insomnia drug Quviviq has gained popularity in the US and Europe recently
The drug, which is used to prevent cerebral vasospasm, is expected to be sold by Handok in Korea, with the company also conducting domestic clinical trials.
According to industry sources on the 26th, Idorsia Pharmaceuticals Korea (President: Minbok Lee) recently applied for the reimbursement of its Pivlaz Inj to the Health Insurance Review and Assessment Service.
The company quickly started the reimbursement listing process after obtaining marketing authorization from the Ministry of Food and Drug
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)